TrialCancer discovery2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Yelena Y Janjigian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
185 papers cite itlatest 60 shown
this paperpooled ittrialcites it